A New Fast-Acting Sublingual Fentanyl (Recivit®) for Treating Breakthrough Cancer Pain

European Oncology and Haematology - United Kingdom
doi 10.17925/eoh.2014.10.1.12
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Touch Medical Media, Ltd.

Related search

Intranasal Fentanyl for Breakthrough Pain Control

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2012English

Cost-Effectiveness Analysis of Oral Fentanyl Formulations for Breakthrough Cancer Pain Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Role of Intranasal Fentanyl in Breakthrough Pain Management in Cancer Patients

Cancer Management and Research
Oncology
2010English

Budget Impact Analysis of the Fentanyl Buccal Tablet for Treatment of Breakthrough Cancer Pain

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2013English

An Italian Survey on the Attitudes in Treating Breakthrough Cancer Pain in Hospice

Supportive Care in Cancer
Oncology
2010English

Canadian Recommendations for the Management of Breakthrough Cancer Pain

Current Oncology
Oncology
2016English

Breakthrough Cancer Pain and Rational Drug Use

Supportive Care in Cancer
Oncology
2017English

A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting

Cancer Research and Treatment
Cancer ResearchOncology
2016English

A Study of Transdermal Fentanyl in Cancer Pain at Aichi-Cancer Center

Yakugaku Zasshi
PharmacologyPharmaceutical Science
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy